Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period.
This is 3rd edition report on Hepatitis C Drugs Industry by Renub Research. Report titled 'Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global' provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.
1. Hepatitis C Drugs Market & Forecast (Chapter 2)
2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
3. Hepatitis C – Pipeline Drugs Sales & Forecast (Chapter 4)
4. Hepatitis C Deals & Acquisitions (Chapter 5)
5. Hepatitis C – Company Wise Clinical Trial Analysis (Chapter 6)
Hepatitis C – Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)
1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
5. Olysio
6. Sovaldi/Harvoni
7. HCV Franchise
8. Viekira Pak
Hepatitis C – Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)
1. Drug A (Merck & Co. Inc.)
2. Drug B (Merck & Co. Inc.)
3. Drug C (Bristol-Myers Squibb)
Hepatitis C – Company Wise Clinical Trial Analysis (Chapter No.5)
1. AbbVie
2. Bristol-Myers Squibb (BMS)
3. Gilead Sciences
4. Merck & Co. Inc.
5. Tibotec/Janssen Therapeutics
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
This is 3rd edition report on Hepatitis C Drugs Industry by Renub Research. Report titled 'Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global' provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.
1. Hepatitis C Drugs Market & Forecast (Chapter 2)
2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
3. Hepatitis C – Pipeline Drugs Sales & Forecast (Chapter 4)
4. Hepatitis C Deals & Acquisitions (Chapter 5)
5. Hepatitis C – Company Wise Clinical Trial Analysis (Chapter 6)
Hepatitis C – Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)
1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
5. Olysio
6. Sovaldi/Harvoni
7. HCV Franchise
8. Viekira Pak
Hepatitis C – Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)
1. Drug A (Merck & Co. Inc.)
2. Drug B (Merck & Co. Inc.)
3. Drug C (Bristol-Myers Squibb)
Hepatitis C – Company Wise Clinical Trial Analysis (Chapter No.5)
1. AbbVie
2. Bristol-Myers Squibb (BMS)
3. Gilead Sciences
4. Merck & Co. Inc.
5. Tibotec/Janssen Therapeutics
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
1. EXECUTIVE SUMMARY
2. HEPATITIS C DRUGS – MARKET & FORECAST
3. HEPATITIS C – APPROVED DRUGS SALES & FORECAST
3.1 Pegasys Sales & Forecast
3.2 Pegintron Sales & Forecast
3.3 Incivek Sales
3.4 Victrelis Sales & Forecast
3.5 Olysio Sales & Forecast
3.6 Sovaldi / Harvoni Sales & Forecast
3.7 HCV Franchise Sales & Forecast
3.8 Viekira Pak Sales & Forecast
4. HEPATITIS C - PIPELINE DRUGS SALES FORECAST
4.1 Drug A of (Merck & Co. Inc.)
4.2 Drug B of (Merck & Co. Inc.)
4.3 Drug C of (Bristol-Myers Squibb)
5. HEPATITIS C – DEALS & ACQUISITIONS
6. HEPATITIS C – COMPANY WISE CLINICAL TRIALS ANALYSIS
6.1 AbbVie – Clinical Trials
6.1.1 Phase III
6.1.2 Phase II
6.1.3 Phase I
6.2 Bristol-Myers Squibb (BMS) – Clinical Trials
6.2.1 Phase III
6.2.2 Phase II
6.3 Gilead Sciences – Clinical Trials
6.3.1 Phase II
6.4 Merck & Co. Inc. – Clinical Trials
6.4.1 Phase IV
6.4.2 Phase III
6.4.3 Phase II
6.4.4 Phase I
6.5 Tibotec / Janssen Therapeutics – Clinical Trials
6.5.1 Phase IV
6.5.2 Phase III
6.5.3 Phase II
6.5.4 Phase I
2. HEPATITIS C DRUGS – MARKET & FORECAST
3. HEPATITIS C – APPROVED DRUGS SALES & FORECAST
3.1 Pegasys Sales & Forecast
3.2 Pegintron Sales & Forecast
3.3 Incivek Sales
3.4 Victrelis Sales & Forecast
3.5 Olysio Sales & Forecast
3.6 Sovaldi / Harvoni Sales & Forecast
3.7 HCV Franchise Sales & Forecast
3.8 Viekira Pak Sales & Forecast
4. HEPATITIS C - PIPELINE DRUGS SALES FORECAST
4.1 Drug A of (Merck & Co. Inc.)
4.2 Drug B of (Merck & Co. Inc.)
4.3 Drug C of (Bristol-Myers Squibb)
5. HEPATITIS C – DEALS & ACQUISITIONS
6. HEPATITIS C – COMPANY WISE CLINICAL TRIALS ANALYSIS
6.1 AbbVie – Clinical Trials
6.1.1 Phase III
6.1.2 Phase II
6.1.3 Phase I
6.2 Bristol-Myers Squibb (BMS) – Clinical Trials
6.2.1 Phase III
6.2.2 Phase II
6.3 Gilead Sciences – Clinical Trials
6.3.1 Phase II
6.4 Merck & Co. Inc. – Clinical Trials
6.4.1 Phase IV
6.4.2 Phase III
6.4.3 Phase II
6.4.4 Phase I
6.5 Tibotec / Janssen Therapeutics – Clinical Trials
6.5.1 Phase IV
6.5.2 Phase III
6.5.3 Phase II
6.5.4 Phase I
LIST OF FIGURES:
Figure 2 1: Global – Hepatitis C Drug Market (Million US$), 2010 – 2014
Figure 2 2: Global – Forecast for Hepatitis C Drug Market (Million US$), 2015 – 2020
Figure 3 1: Global – Pegasys Sales (Million US$), 2005 – 2014
Figure 3 2: Global – Forecast for Pegasys Sales (Million US$), 2015 – 2020
Figure 3 3: Global – Pegintron Sales (Million US$), 2010 – 2014
Figure 3 4: Global – Forecast for Pegintron Sales (Million US$), 2015 – 2020
Figure 3 5: Global – Incivek Sales (Million US$), 2011 – 2014
Figure 3 6: Global – Victrelis Sales & Forecast (Million US$), 2011 – 2015
Figure 3 7: Global – Olysio Sales (Million US$), 2013 – 2014
Figure 3 8: Global – Forecast for Olysio Sales (Million US$), 2015 – 2020
Figure 3 9: Global – Sovaldi/Harvoni Sales (Million US$), 2013 – 2014
Figure 3 10: Global – Forecast for Sovaldi/Harvoni Sales (Million US$), 2015 – 2020
Figure 3 11: Global – HCV Franchise Sales & Forecast (Million US$), 2014 – 2020
Figure 3 12: Hepatitis C Drugs – Viekira Pak, Sovaldi & Harvoni Initial Prescription (Number), 2013, 2014
Figure 3 13: Global – Viekira Pak Sales & Forecast (Million US$), 2014 – 2020
Figure 4 1: Global – Forecast for Vaniprevir (MK-7009) Sales (Million US$), 2015 – 2020
Figure 4 2: Global – Forecast for Grazoprevir/Elbasvir (MK-5172 + MK-8742) Sales (Million US$), 2016 – 2020
Figure 4 3: Global – Forecast for PEG-Interferon Lambda Sales (Million US$), 2015 – 2020
Figure 2 1: Global – Hepatitis C Drug Market (Million US$), 2010 – 2014
Figure 2 2: Global – Forecast for Hepatitis C Drug Market (Million US$), 2015 – 2020
Figure 3 1: Global – Pegasys Sales (Million US$), 2005 – 2014
Figure 3 2: Global – Forecast for Pegasys Sales (Million US$), 2015 – 2020
Figure 3 3: Global – Pegintron Sales (Million US$), 2010 – 2014
Figure 3 4: Global – Forecast for Pegintron Sales (Million US$), 2015 – 2020
Figure 3 5: Global – Incivek Sales (Million US$), 2011 – 2014
Figure 3 6: Global – Victrelis Sales & Forecast (Million US$), 2011 – 2015
Figure 3 7: Global – Olysio Sales (Million US$), 2013 – 2014
Figure 3 8: Global – Forecast for Olysio Sales (Million US$), 2015 – 2020
Figure 3 9: Global – Sovaldi/Harvoni Sales (Million US$), 2013 – 2014
Figure 3 10: Global – Forecast for Sovaldi/Harvoni Sales (Million US$), 2015 – 2020
Figure 3 11: Global – HCV Franchise Sales & Forecast (Million US$), 2014 – 2020
Figure 3 12: Hepatitis C Drugs – Viekira Pak, Sovaldi & Harvoni Initial Prescription (Number), 2013, 2014
Figure 3 13: Global – Viekira Pak Sales & Forecast (Million US$), 2014 – 2020
Figure 4 1: Global – Forecast for Vaniprevir (MK-7009) Sales (Million US$), 2015 – 2020
Figure 4 2: Global – Forecast for Grazoprevir/Elbasvir (MK-5172 + MK-8742) Sales (Million US$), 2016 – 2020
Figure 4 3: Global – Forecast for PEG-Interferon Lambda Sales (Million US$), 2015 – 2020
LIST OF TABLES:
Table 5 1: Hepatitis C – Deals & Acquisitions in the anti-HCV Drug Space, 2004 – 2012
Table 5 1: Hepatitis C – Deals & Acquisitions in the anti-HCV Drug Space, 2004 – 2012
